{
  "slug": "breast-cancer",
  "question": "What are the odds of dying from breast cancer?",
  "category": "cancer",
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Breast cancer is the single most-feared disease in several women’s health surveys. A 2005 Society for Women’s Health Research poll found 22% of women named it the disease they feared most, ahead of heart disease despite the latter killing roughly seven times as many women. Almost everyone has heard the \"1 in 8\" figure — but that figure is the lifetime probability of *diagnosis*, not death. Public intuition reliably conflates the two, which is why breast cancer lives in the \"calibrated about diagnosis, wrong about mortality\" bucket.\n",
    "rough_estimate": "Most adults quote 1 in 8 and implicitly read it as a death rate",
    "kind": "survey",
    "survey_source": {
      "title": "Women Most Fear Cancer, But Heart Disease Is The Top Killer",
      "publisher": "The Newtown Bee (reporting Society for Women's Health Research survey)",
      "url": "https://www.newtownbee.com/08262005/women-most-fear-cancer-but-heart-disease-is-the-top-killer/",
      "year": 2005
    }
  },
  "native": {
    "display": "~670,000 breast cancer deaths per year globally (women)",
    "numerator": 670000,
    "denominator": 4000000000,
    "unit": "per year",
    "population": "global women, all ages"
  },
  "normalized": {
    "lifetime_us_adult": 0.017,
    "display": "1 in ~59 lifetime (global adult women)",
    "log_value": -1.77,
    "assumptions": "WHO reports ~670,000 global breast cancer deaths per year against an adult female population of roughly 3-4 billion, which gives an annual per-woman hazard near 1.7 per 10,000. Age-weighted over ~60 years of remaining adult life (most breast cancer deaths occur between ages 50 and 74, so the hazard in the second half of adult life is several-fold higher than the flat average), the implied global lifetime breast-cancer mortality for women sits around 1.5-2.0%. The American Cancer Society’s direct SEER-based estimate for US women is 2.3% (~1 in 43) — higher than the global figure primarily because competing mortality in low- and middle-income countries removes many women from the denominator before they reach peak breast-cancer age, not because breast cancer is \"safer\" in LMICs; case fatality is in fact worse there due to later diagnosis. Headline figure 0.017 (≈ 1 in 59) for the global women baseline, with an uncertainty band reaching up to the US direct estimate of ~0.023. Men are excluded from this headline (see regional breakdown) because their risk is roughly 100× lower and folding both sexes into one number hides the relevant asymmetry. Scope is global-adult-lifetime.\n",
    "uncertainty": {
      "low": 0.013,
      "high": 0.026
    },
    "scope": "subgroup_lifetime"
  },
  "sources": [
    {
      "url": "https://www.who.int/news-room/fact-sheets/detail/breast-cancer",
      "title": "Breast cancer — fact sheet",
      "publisher": "World Health Organization",
      "source_type": "govt_report",
      "statistic": "2.3 million women diagnosed with breast cancer and 670,000 deaths globally in 2022",
      "excerpt": "\"In 2022, there were an estimated 2.3 million women diagnosed with breast cancer and 670 000 deaths globally. [...] Approximately 99% of breast cancers occur in women and 0.5-1% of breast cancers occur in men.\"\n",
      "source_date": "2024-03-13",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260405045005/https://www.who.int/news-room/fact-sheets/detail/breast-cancer",
      "calculation_notes": "WHO republishes IARC GLOBOCAN 2022 breast-cancer totals: ~2.3M new cases and ~670K deaths among women per year. Divided naively across ~3.5B adult women worldwide that is ~1.9 per 10,000 per year. Age-weighting (most breast cancer deaths occur between 50 and 74) puts the realistic cumulative lifetime mortality near 1.5-2% globally, consistent with — and slightly below — the ACS direct US estimate of ~2.3%.\n",
      "independence_note": "WHO breast-cancer fact sheet republishes IARC GLOBOCAN headline numbers. Treat as partially dependent with any other IARC-derived source; used here as the authoritative top-line institutional citation.\n"
    },
    {
      "url": "https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html",
      "title": "How Common Is Breast Cancer?",
      "publisher": "American Cancer Society",
      "source_type": "reputable_reference",
      "statistic": "Lifetime US female risk of developing breast cancer ~13% (1 in 8); lifetime risk of dying from breast cancer ~2.3% (1 in 43)",
      "excerpt": "\"Overall, the average risk of a woman in the United States developing breast cancer sometime in her life is about 13%. This means there is a 1 in 8 chance she will develop breast cancer. [...] The chance that any woman will die from breast cancer is about 1 in 43 (about 2.3%).\"\n",
      "source_date": "2025-01-16",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260412072019/https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html",
      "calculation_notes": "ACS gives both figures explicitly. Lifetime incidence 13% (1 in 8) and lifetime mortality 2.3% (1 in 43) — a roughly 5.5× gap between diagnosis and death. This is the single most important calibration point on the page: most readers quote \"1 in 8\" as if it were a death rate, when it is in fact the *incidence* rate. The US 2.3% anchors the upper end of the global uncertainty band.\n",
      "independence_note": "ACS derives its US lifetime-probability figures from SEER incidence and mortality data (NCI). SEER is a population-based cancer registry pipeline methodologically independent of IARC GLOBOCAN, which compiles national registry data globally.\n"
    },
    {
      "url": "https://seer.cancer.gov/statfacts/html/breast.html",
      "title": "Cancer Stat Facts: Female Breast Cancer",
      "publisher": "National Cancer Institute / SEER Program",
      "source_type": "govt_report",
      "statistic": "5-year relative survival 91.7%; localized-stage 5-year survival 100.0%; ~13.0% lifetime risk of diagnosis",
      "excerpt": "\"Approximately 13.0 percent of women will be diagnosed with female breast cancer at some point during their lifetime, based on 2018-2021 data. [...] The 5-year relative survival for females with breast cancer is 91.7%, based on SEER 21 data from 2015-2021.\"\n",
      "source_date": "2025-04-17",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260406234603/https://seer.cancer.gov/statfacts/html/breast.html",
      "calculation_notes": "SEER is the primary US surveillance dataset feeding the ACS lifetime-probability figures above. The 91.7% 5-year relative survival — and the 100% figure for localized-stage disease, which is ~64% of new diagnoses — is the mechanism that makes the diagnosis/death gap so large. Most breast cancer diagnosed in wealthy countries is not a death sentence.\n",
      "independence_note": "SEER is the upstream data source that ACS cites; treat these two as partially dependent. SEER is included as the authoritative primary-pipeline citation.\n"
    },
    {
      "url": "https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html",
      "title": "Breast Cancer Risk Factors You Cannot Change",
      "publisher": "American Cancer Society",
      "source_type": "reputable_reference",
      "statistic": "BRCA1/BRCA2 pathogenic variant carriers: ~70% lifetime breast cancer risk by age 80",
      "excerpt": "\"On average, a woman with a BRCA1 or BRCA2 gene mutation has up to a 7 in 10 chance of getting breast cancer by age 80.\"\n",
      "source_date": "2024-12-19",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413164045/https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html",
      "calculation_notes": "~70% lifetime breast cancer risk for BRCA1/BRCA2 carriers vs ~13% baseline for US women = roughly 5× absolute incidence elevation. BRCA pathogenic variants affect roughly 1 in 400-500 women in the general population, so the subgroup is real but small; the great majority of breast cancer occurs in non-carriers. Used to calibrate the personal_factor_multipliers block below.\n",
      "independence_note": "ACS BRCA guidance synthesises results from the BRCA1/2 cohort literature (BCLC, kConFab, CARRIERS, etc.). Addresses genetic subgroup risk rather than the population-level mortality headline, so is methodologically distinct from the WHO/IARC and SEER pipelines above; used only to calibrate the personal-factor multipliers.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Any cancer death (lifetime, global adult)",
      "lifetime_us_adult": 0.14
    },
    {
      "label": "Stroke death (lifetime, global adult)",
      "lifetime_us_adult": 0.067
    },
    {
      "label": "Car crash death (lifetime, US)",
      "lifetime_us_adult": 0.0108
    },
    {
      "label": "Homicide death (lifetime, US)",
      "lifetime_us_adult": 0.00348
    }
  ],
  "regional_breakdown": [
    {
      "region": "Global average, women",
      "probability": 0.017,
      "notes": "~670K deaths/yr across ~3.5B adult women (WHO / IARC GLOBOCAN 2022)"
    },
    {
      "region": "US women",
      "probability": 0.023,
      "notes": "ACS direct SEER-based estimate: ~1 in 43 lifetime death, alongside ~1 in 8 lifetime diagnosis"
    },
    {
      "region": "East Africa / LMIC women",
      "probability": 0.022,
      "notes": "Lower age-standardized incidence than high-income countries but meaningfully higher case-fatality due to late-stage diagnosis; the two effects roughly cancel and the lifetime death figure is comparable to the US"
    },
    {
      "region": "Men (all regions)",
      "probability": 0.0003,
      "notes": "Male breast cancer is ~100× rarer; roughly 0.5-1% of all breast cancers occur in men"
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "BRCA1/BRCA2 pathogenic variant",
      "multiplier": 4,
      "notes": "Lifetime breast cancer risk ~70% vs ~13% baseline for women; the sharpest single risk elevation, but affects only roughly 1 in 400-500 women"
    },
    {
      "factor": "First-degree family history of breast cancer",
      "multiplier": 2,
      "notes": "Aggregate figure across population studies; higher if multiple relatives or early-onset diagnosis"
    },
    {
      "factor": "Dense breast tissue (BI-RADS C/D)",
      "multiplier": 1.5,
      "notes": "Dense tissue both elevates risk and masks tumors on conventional mammography"
    },
    {
      "factor": "Regular mammography screening from recommended age",
      "multiplier": 0.7,
      "notes": "Mortality reduction, not incidence reduction — screening catches cancers earlier, shifting the stage distribution toward localized disease where 5-year survival is ~100%"
    },
    {
      "factor": "No risk factors, screening-compliant, healthy lifestyle",
      "multiplier": 0.6
    }
  ],
  "short_label": "Breast cancer",
  "myth_framing": "calibrated",
  "outcome_severity": "fatal",
  "exposure_pattern": "recurring",
  "outcome_type": "chronic_illness",
  "valence": "negative",
  "caveats": "This entry is lifetime *mortality* from breast cancer, not incidence. The widely quoted \"1 in 8\" figure is the lifetime probability a US woman will be *diagnosed* with invasive breast cancer; the lifetime probability she will *die* of it is about 1 in 43 per ACS — roughly 5.5× smaller. The diagnosis/death gap is the single most consistent perception mistake visitors make on this site. Survival also depends heavily on stage at diagnosis: SEER’s 5-year relative survival is 100% for localized disease (~64% of cases), 87% for regional spread, and 33% for distant metastases, so the aggregate number smooths over a very uneven outcome distribution. Male breast cancer exists but is roughly 100× rarer and is excluded from the headline number — see the regional breakdown for the male-specific figure.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 4,
    "d4": 5,
    "d5": 5,
    "d6": 5,
    "d7": 5,
    "d8": 5,
    "avg": 4.875,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "likelier-phase-5-agent",
  "last_reviewed": "2026-04-11",
  "reviewed": true,
  "generated_at": "2026-04-11",
  "image": {
    "alt": "A single pale circular shape softly overlapping a smaller circle on a muted rose-grey background, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/breast-cancer"
}